Lidds AB (LIDDS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Lidds AB (LIDDS) has a cash flow conversion efficiency ratio of -0.413x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-616.00K ≈ $-66.29K USD) by net assets (Skr1.49 Million ≈ $160.56K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LIDDS defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Lidds AB - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how Lidds AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Lidds AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Lidds AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Wildpack Beverage Inc
V:CANS
|
0.068x |
|
Israel Opportunity - Energy Resources LP
TA:ISOP-L
|
-0.055x |
|
Kavango Resources PLC
LSE:KAV
|
-0.160x |
|
MEDIMI AB AK
F:79T
|
-0.182x |
|
Alkemy Capital Investments Plc
LSE:ALK
|
0.321x |
|
Reco International Group Inc
V:RGI
|
0.037x |
|
Vaxil Bio Ltd
V:VXL
|
-0.042x |
|
BLUERUSH Media Group Corp
V:BTV
|
-0.015x |
Annual Cash Flow Conversion Efficiency for Lidds AB (2013–2024)
The table below shows the annual cash flow conversion efficiency of Lidds AB from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Lidds AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr6.18 Million ≈ $664.96K |
Skr-5.43 Million ≈ $-584.68K |
-0.879x | +53.39% |
| 2023-12-31 | Skr13.90 Million ≈ $1.50 Million |
Skr-26.22 Million ≈ $-2.82 Million |
-1.886x | +18.65% |
| 2022-12-31 | Skr15.35 Million ≈ $1.65 Million |
Skr-35.59 Million ≈ $-3.83 Million |
-2.319x | -163.81% |
| 2021-12-31 | Skr48.51 Million ≈ $5.22 Million |
Skr-42.64 Million ≈ $-4.59 Million |
-0.879x | -37.23% |
| 2020-12-31 | Skr42.81 Million ≈ $4.61 Million |
Skr-27.42 Million ≈ $-2.95 Million |
-0.641x | -470.12% |
| 2019-12-31 | Skr152.13 Million ≈ $16.37 Million |
Skr-17.09 Million ≈ $-1.84 Million |
-0.112x | -1131.42% |
| 2018-12-31 | Skr158.52 Million ≈ $17.06 Million |
Skr-1.45 Million ≈ $-155.64K |
-0.009x | +89.16% |
| 2017-12-31 | Skr127.25 Million ≈ $13.69 Million |
Skr-10.71 Million ≈ $-1.15 Million |
-0.084x | -352.72% |
| 2016-12-31 | Skr112.52 Million ≈ $12.11 Million |
Skr-2.09 Million ≈ $-225.21K |
-0.019x | +74.68% |
| 2015-12-31 | Skr99.77 Million ≈ $10.74 Million |
Skr-7.33 Million ≈ $-788.75K |
-0.073x | -3.47% |
| 2014-12-31 | Skr96.37 Million ≈ $10.37 Million |
Skr-6.84 Million ≈ $-736.33K |
-0.071x | -1.37% |
| 2013-12-31 | Skr75.21 Million ≈ $8.09 Million |
Skr-5.27 Million ≈ $-566.87K |
-0.070x | -- |
About Lidds AB
LIDDS AB (publ), a drug delivery company, develops pharmaceutical products based on its NanoZolid proprietary technology for the treatment of cancer and other diseases in Sweden. Its product pipeline comprises Nanoimod, a NanoZolid-formulated agatolimod, as well as a toll-like receptor 9 (TLR9) agonist, which is in preclinical trial; Nanodotax, a NanoZolid-formulated docetaxel, which is a chemoth… Read more